Complement Therapeutics announces SAB to drive pipeline

Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases.

The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness. The company hopes to evaluate CTx001 in other complement-mediated conditions.

The company’s Clinical & Scientific Advisory Board will now work alongside management and scientific teams to advance Complement Therapeutics’ pipeline of products targeting complement-related diseases.

Board members include:

Robyn Guymer, Ph.D – Professor Robyn Guymer is the Deputy Director and Head of Macular Research at Centre for Eye Research Australia, leading a team that is primarily investigating Age-related macular degeneration (AMD), and has authored over 300 peer-reviewed papers.

Jeff Heier, MD – Dr. Jeffrey S. Heier is the Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the most prestigious ophthalmologic practices in the United States

Peter Kaiser, MD – Dr Peter K. Kaiser, M.D., is the Director of the Center for Ocular Research and Evaluation (CORE) and a RO1-funded principal investigator at the National Institute of Health.

Paul Morgan, Ph.D – Professor Paul Morgan brings over 30 years’ worth of experience in the complement system and is currently based at Cardiff University in the Division of Infection and Immunity.

Nadia Waheed, MD, MPH – Dr. Nadia Waheed was the Chief Medical Officer at Gyroscope Therapeutics and previously the Director of the Boston Image Reading Center.  She also established the Retina Unit at the Shifa Hospital.

Official comments

“The creation of this expert advisory board with renowned international specialists will provide CTx with invaluable counsel across a range of topics including complement biology, ophthalmology, preclinical and clinical development. We are honoured that such esteemed experts have agreed to join our team to support the company as we continue to build our momentum and ensure we enter the clinic with the strongest possible development plan,” said Dr Rafiq Hasan, CEO of Complement Therapeutics.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free